AE, adverse event; PD, progressive disease. -, Pelucchi C, Gallus S, Garavello W, et al. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination. Chaque essai clinique est conçu afin de répondre à certaines questions de la phase de recherche. Essai clinique de Phase III - Gynécologie - Col utérus. Both a pharmacologist and an endocrinologist have reviewed each case to select only those of peripheral thyroiditis (thyrotoxicosis and hypothyroidism). Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Lancet Oncol. Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, Takahashi K, Cheng JD, Bang YJ. 2. ... évaluant l’impact clinique … Keytruda ® (pembrolizumab) – Avis d’efficience HAS / Service évaluation économique et santé publique 5 . CA Cancer J Clin. 364449 résultats au total . American Cancer Society head and neck cancer survivorship care guideline. Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma. 4. Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Bâle, Coire, Lucerne, Saint-Gall. Essais cliniques; Etude comparant un traitement par pembrolizumab et le traitement standard par brentuximab vedotin chez des patients atteints d’un lymphome classique de Hodgkin réfractaire ou récidivant après au moins deux traitements par chimiothérapie ou une autogreffe Six-month progression-free survival and overall survival rates were 23% and 59%, respectively. N Engl J Med. P30 CA016086/CA/NCI NIH HHS/United States, NCI CPTC Antibody Characterization Program, Ferlay J, Soerjomataram I, Dikshit R, et al. Urgences uniquement : +33 (0)1 42 11 50 00 Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Epub 2018 Feb 21. Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. 2006;29:193–198. Ouvert depuis le: 12.21.2020. Consort diagram. Filter by: Filter by ... Etude clinique (24) Phase I/II (17) Phase II/III (6) Phase IV (1) Essai. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. -. 2019 May;31(3):146-151. doi: 10.1097/CCO.0000000000000522. Trial registration: Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Éligible à participer à un essai clinique d’un traitement anticancéreux alternatif ciblant leur maladie et qui est ouvert à l’inclusion en France. Identifier les populations pour lesquelles un bénéfice clinique est attendu lors d’un traitement par le produit à l’essai. EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study - DE. Premièrement, l’essai clinique … Woolaver RA, Wang X, Krinsky AL, Waschke BC, Chen SMY, Popolizio V, Nicklawsky AG, Gao D, Chen Z, Jimeno A, Wang XJ, Wang JH. Epub 2016 May 27. Abstract Background E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of … Clinical trials … Essais cliniques; MK3475-365 Phase I/II clinical trial - Prostate. Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer. NCT03865212 Recrutement . Curr Opin Oncol. Research Committee(s) Melanoma. J Immunother Cancer. (B) Treatment exposure and response duration in responders (all responders, n = 24). 200 mg fixed dose i.v. Source : rapport technique de l’industriel. Éligible à participer à un essai clinique d’un traitement anticancéreux alternatif ciblant leur maladie et qui est ouvert à l’inclusion en France. Les essais cliniques sont classés par localisation, avec un descriptif résumant leurs objectifs et leur déroulement ainsi que les médecins investigateurs. Essais cliniques; MK7902-007 (LEAP-007) Phase III clinical trial - Appareil pulmonaire. Patients who received one or more doses of pembrolizumab were included in analyses. All trials on the list are supported by NCI.. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. 3. MK3475-826 (Keynote-826) Gynécologie - Col utérus. Would you like email updates of new search results? Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. NCT04717154. Int J Mol Sci. II. AcSé Pembrolizumab Promoteur. Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 … Public cible . Efficacy of pembrolizumab on the basis of RECIST (v1.1; Response Evaluation Criteria in…, (A) Association of efficacy and programmed death-ligand 1 (PD-L1) expression. Les cancers pris en charge à l'Institut Curie, Prise en charge de nos patients : les étapes, Mettre à disposition de nouvelles thérapies plus rapidement, Portrait - Franck Bourdeaut, pédiatre oncologue, chercheur à SIREDO, Portrait - Sandy Azzi-Hatem, manager et chargée d’affaires du PMS Oncopédiatrie, L’Institut Curie partenaire de l’Agence Française de Développement dans la lutte contre le cancer en Tanzanie, Les services en cancérologie dédiés aux patients internationaux. Wuerdemann N, Pütz K, Eckel H, Jain R, Wittekindt C, Huebbers CU, Sharma SJ, Langer C, Gattenlöhner S, Büttner R, Speel EJ, Suchan M, Wagner S, Quaas A, Klussmann JP. ... 2. MK-3475-991 / Keynote … Drug: Gemcitabine Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. HHS Clinical trials look at new ways to prevent, detect, or treat disease. Il s'agit d'une étude d'innocuité, d'efficacité et de pharmacocinétique (PK) du vibostolimab (MK-7684) comme en monothérapie et en association avec le pembrolizumab (MK-3475) ou le pembrolizumab plus pémétrexed et carboplatine chez les adultes atteints de tumeurs solides métastatiques pour lesquelles il n'existe pas de thérapie qui devrait apporter un bénéfice clinique. BET115521. HIPANIV A phase I study evaluating safety and efficacy of Hepatic Intra-Arterial administration of... Médecin investigateur. 2014;86:212–229. MELANOME => 2 nouvelles molécules révoluonnaires Pembrolizumab (Keytruda) 2mg/kg IV tous les 21 jours ... Cas clinique : paent inclus dans essai … J Clin Oncol. Essais cliniques canadiens ouverts et en recrutement (Mis à jour: 17 juillet 2017) Pour plus d'informations sur chaque essai clinique (critères d'inclusion et d'exclusion), cliquez sur le nom de l'essai afin d'être redirigé vers www.clinicaltrials.gov. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Les derniers essais cliniques dans le monde sur les tumeurs de cerveau 2017-2019 Pour connaître rapidement les essais cliniques d'immunothérapie en cours sur clinicaltrials cliquer ici -saisir dans le 1er cadre de recherche, la maladie, glioblastoma puis dans le 2ème champ immunotherapy par exemple et en 3ème le pays où vous êtes puis cliquer sur recherchez toutes les études. CheckMate 143 (NCT 02017717) était le premier grand essai clinique randomisé de l'inhibition de la voie PD-1/PD-L1 du glioblastome, y compris une comparaison de nivolumab avec l'antiangiogénique … Int J Radiat Oncol Biol Phys. USA.gov. Site : Saint-Cloud. Conclusion Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC. identifier des sous-groupes de patients qui pourraient bénéficier du traitement. COVID-19 is an emerging, rapidly evolving situation. Conditions: Osteoarthritis, Knee . Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer Sci. This site needs JavaScript to work properly. 2021 Jan 18;13(2):338. doi: 10.3390/cancers13020338. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. 12 résultats au total. The clinical trials on this list are studying Olaparib. Open. (B and C) Kaplan-Meier estimates of (B) progression-free survival (PFS) and (C) overall survival (OS) on the basis of a positive expression cutoff of ≥ 1% in tumor and immune cells (all-patients-as-treated population, N = 132). • Taux de réponse varie de 10 à 26 % • Variable en fonction de la molécule • Variable en fonction de la ligne thérapeutique • Variable en fonction de sous-groupes: • PD-L1+ • MSI+ • EBV+. Efficacy of pembrolizumab on the basis of RECIST (v1.1; Response Evaluation Criteria in Solid Tumors) by central imaging vendor review. (A) Maximum percentage change from baseline in target lesions. Overall response by…, NLM National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Adulte. Korpela SP, Hinz TK, Oweida A, Kim J, Calhoun J, Ferris R, Nemenoff RA, Karam SD, Clambey ET, Heasley LE. Activated. Muté Non muté Mok et al. AcSé PEMBROLIZUMAB:
Accès sécurisé au pembrolizumab pour des patients adultes porteurs de certains types de cancers rares. Human papillomavirus and survival of patients with oropharyngeal cancer. The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. NCT04717167. The ClinicalTrials.gov results database was launched in September 2008 to implement Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (PDF), which requires the submission of "basic results" for certain clinical trials, … ClinicalTrials.gov NCT01848834. The EFS following administration of pembrolizumab and placebo, both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies, as determined by the investigator for participants with a CPS ≥1 will be presented. Clinical trials are research studies that involve people. Myélome récemment diagnostiqué Phase I 1. Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% received two or more lines of therapy for R/M disease.